PIUR IMAGING Joins NVIDIA Inception Program

PIUR IMAGING GmbH today announced it has joined NVIDIA Inception, a program designed to nurture startups revolutionizing industries with advancements in AI and data sciences.

PIUR´s tomographic ultrasound solutions turn any standard ultrasound system into a tomographic 3D imaging device, bridging the gap between 2D ultrasound and regular tomographic imaging modalities. With any conventional 2D ultrasound transducer, high-resolution tomographic images can be generated. While standard ultrasound requires on-the-spot assessment of the images, PIUR´s 3D ultrasound volumes of entire structures or organs allow retrospective diagnosis at any time.

NVIDIA Inception will allow PIUR IMAGING to further advance their portfolio of AI applications for automatic image analysis and visualization of tomographic 3D ultrasound data. The program will also offer PIUR IMAGING the opportunity to collaborate with industry-leading experts and other AI-driven organizations.

“We are very excited that we have been selected for this exclusive program. There are many very innovative companies in the NVIDIA Inception program and I believe access to this great network is a big step towards success”, says Frederik Bender, CEO, PIUR IMAGING.

NVIDIA Inception is a program that helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, marketing support, and technology assistance, which provides startups with the fundamental tools to help them grow.

About PIUR IMAGING: 

piur imaging GmbH is a medical device company headquartered in Vienna, Austria. Founded in 2014, PIUR´s vision is to maximize access to safe, accurate and non-invasive image diagnostics through AI-driven tomographic ultrasound solutions.

For further information, please contact:

Frederik Bender, bender@piurimaging.com, +43 – 1 – 26 50 160

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.